Surv Biopharma
Latest round
- Series B
Last raised
- Dec 2025
Total raised
- $14M
Investors
- 13
About Surv Biopharma
Established in 2022 and based in Kagoshima, Japan, Surv Biopharma Inc. is a pharmaceutical development and support company that engages in clinical applications, diagnostics, consulting, manufacturing, and sales support services. As of January 2023, Kenichiro Obasu serves as the CEO of the company. In November 2025, Surv Biopharma Inc. The company provides a drug discovery technology platform, which is a replicating adenovirus with multifactorial control that affects only cancer cells and not normal cells (m-CRA). The company is working on a practical application of virotherapy based on the developed oncolytic virus.m-CRA series, which target survivin, a protein that is only found in cancer cells. Surv Biopharma Inc. revenue by developing and licensing innovative oncolytic virus therapies for cancer treatment, supported by strategic partnerships and clinical trial collaborations.
Who invested in Surv Biopharma
13 investors across 2 rounds
See all investors in Surv Biopharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Surv Biopharma
Who invested in Surv Biopharma?
Surv Biopharma has 13 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Surv Biopharma raised?
Surv Biopharma has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Surv Biopharma last raise money?
Surv Biopharma's most recent round on record is a Series B, in Dec 2025.
What does Surv Biopharma do?
Established in 2022 and based in Kagoshima, Japan, Surv Biopharma Inc.
Where is Surv Biopharma headquartered?
Surv Biopharma is headquartered in Kagoshima-shi, Japan.
Which VCs invest in companies like Surv Biopharma?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Surv Biopharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Surv Biopharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.